AN OVERVIEW OF ANTIRETROVIRAL THERAPY ON PLWHA IN MANOKWARI, FAKFAK AND SORONG CITY, WEST PAPUA
Antiretroviral treatment is used to suppress the HIV in People Living with HIV AIDS (PLWHA) because it improves quality of life and prevents death. Manokwari Regency, Fak-Fak and Sorong City had high HIV AIDS cases in West Papua Province. The aim of this study was to identify the clinical, immunological, and compliance conditions of antiretroviral treatment of PLWHA in these 3 locations. The research design was cross sectional. Respondents were PLHIV who were on antiretroviral therapy for at least 6 months, men and women over the age of 15. Data were obtained through interviews, medical records and CD4 examinations. The majority of respondents were productive age groups 15-45 years old, working and women, who did not have TB after treatment even though the majority of respondents at the start of therapy had stage 3-4 HIV disease, normal Body Mass Index, CD4 cell count above 350 cells/mm³ (except in Fakfak). Good therapeutic compliance in Manokwari (87.8%), Sorong City (79.8%), Fakfak (57.1%). There was a relationship between TB status, stage of illness, adherence to therapy with CD4 counts of study respondents.
2. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kemenkes RI. Laporan perkembangan HIV AIDS dan penyakit Infeksi Menular Seksual (PIMS) Triwulan II Tahun 2019 [Internet]. Jakarta; 2019. Available from: https://siha.depkes.go.id/portal/files_upload/Laporan_HIV_TW_II_20192.pdf
3. Dinas Kesehatan Provinsi Papua Barat. Laporan kasus HIV/AIDS triwulan III Tahun 2016 Provinsi Papua Barat. Manokwari; 2016.
4. Ouyang Y, Yin Q, Li W, Li Z, Kong D, Wu Y, et al. Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. Sci Rep [Internet]. 2017;(July):1–12. Available from: http://dx.doi.org/10.1038/s41598-017-05594-5
5. King JM, Jensen BK, Gannon PJ, Akay C. Persistence of HIV-Associated neurocognitive disorder in the era of antiretroviral therapy. INTECHCurrent Perspect HIV Infect [Internet]. 2013;161–206. Available from: http://dx.doi.org/10.5772/52683
6. Murphy K, Weaver C. Janeway"s Immunobiology. 9th ed. New York: Garland Science Taylor & Francis Group; 2017. 1–927 p.
7. Evans DH, Fox MP, Maskew M, McNamara L, MacPhail P, Mathews C, et al. CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on antiretroviral therapy. J Int AIDS Soc [Internet]. 2014;17:1–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165719/pdf/JIAS-17-19139.pdf
8. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan RI. Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral pada orang dewasa. Jakarta: Kementerian Kesehatan RI; 2011.
9. Shafer RW, Rhee S-Y, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS NIH Public Access [Internet]. 2011;23(1):1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2573394/pdf/nihms-65103.pdf
10. World Health Organization. HIV/AIDS data and statistics [Internet]. 2019. 2019 [cited 2020 Mar 3]. Available from: https://www.who.int/hiv/data/en/
11. Sheth AN, Rolle CP, Gandhi M. HIV pre-exposure prophylaxis for women. J virus Erad [Internet]. 2016;2(3):149–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27482454%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4967966
12. Yegorov S, Joag V, Galiwango RM, Good S V., Okech B, Kaul R. Impact of endemic infections on HIV susceptibility in Sub-Saharan Africa. Trop Dis Travel Med Vaccines [Internet]. 2019;5(1):1–18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884859/pdf/40794_2019_Article_97.pdf
13. Price JT, Rosenberg NE, Vansia D, Phanga T, Bhushan NL, Maseko B, et al. Predictors of HIV, HIV risk perception, and HIV worry among adolescent girls and young women in Lilongwe, Malawi. J Acquir Immune Defic Syndr [Internet]. 2018;77(1):53–63. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720919/pdf/nihms909852.pdf
14. Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. PeerJ [Internet]. 2017;2017(12):1–15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733368/pdf/peerj-05-4165.pdf
15. Ahmed M, Merga H, Jarso H. Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: a case-control study. BMC Infect Dis. 2019;19(1):1–7.
16. Sangeda RZ, Mosha F, Aboud S, Kamuhabwa A, Chalamilla G, Vercauteren J, et al. Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. Drug Healthc Patient Saf. 2018;10:79–88.
17. Li X, Ding H, Geng W, Liu J, Jiang Y, Xu J, et al. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China. BMC Infect Dis. 2019;19(1):1–9.
18. Olowookere SA, Fatiregun AA, Ladipo MMA, Abioye-Kuteyi EA, Adewole IF. Effects of adherence to antiretroviral therapy on body mass index, immunological and virological status of Nigerians living with HIV/AIDS. Alexandria J Med [Internet]. 2016;52(1):51–4. Available from: http://dx.doi.org/10.1016/j.ajme.2015.03.001
19. Martinez SS, Campa A, Bussmann H, Moyo S, Makhema J, Huffman FG, et al. Effect of BMI and fat mass on HIV disease progression in HIV- infected, antiretroviral treatment-naïve adults in Botswana. Br J Nutr [Internet]. 2016;155(12):2114–2121. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830121/pdf/nihms943440.pdf
20. Skogmar S, Schön T, Balcha TT, Jemal ZH, Tibesso G, Björk J, et al. CD4 cell levels during treatment for tuberculosis (TB) in Ethiopian adults and clinical markers associated with CD4 lymphocytopenia. PLoS One. 2013;8(12):6–12.
21. Satyanarayan T, Manjunath M, Ranganath M, Mahendra M. Impact of CD4 count in the development of mycobacterium tuberculosis in patients with HIV infection in a tertiary care centre. Int J Adv Med [Internet]. 2018;5(2):340–2. Available from: https://www.ijmedicine.com/index.php/ijam/article/view/1021/850
22. Costa JDM, Torres TS, Coelho LE, Luz PM. Adherence to antiretroviral therapy for HIV / AIDS in Latin America and the Caribbean : systematic review and meta-analysis. J Int AIDS Soc [Internet]. 2018;21(12):1–20. Available from: http://onlinelibrary.wiley.com/doi/10.1002/jia2.25066/full %7C
23. Moral JML, Enriquez BKL, Palmieri PA, Vasquez GMG, Bravo UEE, Edwards JE, et al. Adherence to antiretroviral therapy and the associated factors among people living with HIV / AIDS in Northern Peru : a cross ‑ sectional study. AIDS Res Ther [Internet]. 2019;16(22):1–12. Available from: https://doi.org/10.1186/s12981-019-0238-y
Copyright (c) 2021 Buletin Penelitian Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Publishing your paper with Buletin Penelitian Kesehatan means that the author or authors transfer the copyright to Buletin Penelitian Kesehatan. Buletin Penelitian Kesehatan granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially.
Buletin Penelitian Kesehatan journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
Buletin Penelitian Kesehatan journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.